Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Arno Fritsch

Showing results (1-10 of 16) with videos related to

Pageof 2
Sort By:
Journal of Biopharmaceutical Statistics|September 15, 2015
General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trialsAlex Dmitrienko, Christoph Muysers, Arno Fritsch, et al.
Pulmonary Circulation|March 23, 2018
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studiesRodrigo Cartin-Ceba, Michael Halank, Hossein-Ardeschir Ghofrani, et al.
Heart (British Cardiac Society)|July 3, 2015
Riociguat for pulmonary arterial hypertension associated with congenital heart diseaseStephan Rosenkranz, Hossein-Ardeschir Ghofrani, Maurice Beghetti, et al.
Journal of Toxicology and Environmental Health. Part A|June 24, 2008
Statistical methods for detecting genetic interactions: a head and neck squamous-cell cancer studyKatja Ickstadt, Martin Schäfer, Arno Fritsch, et al.
Cancer|January 18, 2006
Role of exposure to radon and silicosis on the cell type of lung carcinoma in German uranium minersDirk Taeger, Arno Fritsch, Thorsten Wiethege, et al.
Bioinformatics (Oxford, England)|January 30, 2009
Retention time alignment algorithms for LC/MS data must consider non-linear shiftsKatharina Podwojski, Arno Fritsch, Daniel C Chamrad, et al.
The European Respiratory Journal|January 24, 2015
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)Lewis J Rubin, Nazzareno Galiè, Friedrich Grimminger, et al.
The Lancet. Respiratory Medicine|April 13, 2016
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trialHossein-Ardeschir Ghofrani, Friedrich Grimminger, Ekkehard Grünig, et al.
The New England Journal of Medicine|July 26, 2013
Riociguat for the treatment of pulmonary arterial hypertensionHossein-Ardeschir Ghofrani, Nazzareno Galiè, Friedrich Grimminger, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 14, 2017
Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 studyNazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, et al.
Pageof 2

Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Journal of Biopharmaceutical Statistics|September 15, 2015
General guidance on exploratory and confirmatory subgroup analysis in late-stage clinical trialsAlex Dmitrienko, Christoph Muysers, Arno Fritsch, et al.
Pulmonary Circulation|March 23, 2018
Riociguat treatment for portopulmonary hypertension: a subgroup analysis from the PATENT-1/-2 studiesRodrigo Cartin-Ceba, Michael Halank, Hossein-Ardeschir Ghofrani, et al.
Heart (British Cardiac Society)|July 3, 2015
Riociguat for pulmonary arterial hypertension associated with congenital heart diseaseStephan Rosenkranz, Hossein-Ardeschir Ghofrani, Maurice Beghetti, et al.
Journal of Toxicology and Environmental Health. Part A|June 24, 2008
Statistical methods for detecting genetic interactions: a head and neck squamous-cell cancer studyKatja Ickstadt, Martin Schäfer, Arno Fritsch, et al.
Cancer|January 18, 2006
Role of exposure to radon and silicosis on the cell type of lung carcinoma in German uranium minersDirk Taeger, Arno Fritsch, Thorsten Wiethege, et al.
Bioinformatics (Oxford, England)|January 30, 2009
Retention time alignment algorithms for LC/MS data must consider non-linear shiftsKatharina Podwojski, Arno Fritsch, Daniel C Chamrad, et al.
The European Respiratory Journal|January 24, 2015
Riociguat for the treatment of pulmonary arterial hypertension: a long-term extension study (PATENT-2)Lewis J Rubin, Nazzareno Galiè, Friedrich Grimminger, et al.
The Lancet. Respiratory Medicine|April 13, 2016
Predictors of long-term outcomes in patients treated with riociguat for pulmonary arterial hypertension: data from the PATENT-2 open-label, randomised, long-term extension trialHossein-Ardeschir Ghofrani, Friedrich Grimminger, Ekkehard Grünig, et al.
The New England Journal of Medicine|July 26, 2013
Riociguat for the treatment of pulmonary arterial hypertensionHossein-Ardeschir Ghofrani, Nazzareno Galiè, Friedrich Grimminger, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|February 14, 2017
Comparison of hemodynamic parameters in treatment-naïve and pre-treated patients with pulmonary arterial hypertension in the randomized phase III PATENT-1 studyNazzareno Galiè, Friedrich Grimminger, Ekkehard Grünig, et al.
Pageof 2